Research programme: TAK1 kinase inhibitors - Aclaris Therapeutics

Drug Profile

Research programme: TAK1 kinase inhibitors - Aclaris Therapeutics

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Confluence Life Sciences
  • Developer Aclaris Therapeutics
  • Class Small molecules
  • Mechanism of Action MAP kinase kinase kinase 7 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cryopyrin-associated periodic syndromes
  • No development reported Pancreatic cancer

Most Recent Events

  • 08 Aug 2017 Confluence Life Sciences has been acquired by Aclaris Therapeutics
  • 16 Jul 2016 No recent reports of development identified for research development in Pancreatic-cancer in USA (PO)
  • 22 Oct 2014 Confluence Life Sciences receives SBIR grant for TAK1 kinase inhibitor development in Cryopyrin associated Periodic Syndromes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top